Glutamate-induced glioma cell proliferation is prevented by functional expression of the glutamate transporter GLT-1  by Vanhoutte, Nicolas & Hermans, Emmanuel
FEBS Letters 582 (2008) 1847–1852Glutamate-induced glioma cell proliferation is prevented by
functional expression of the glutamate transporter GLT-1
Nicolas Vanhoutte, Emmanuel Hermans*
Laboratoire de Pharmacologie Expe´rimentale, Universite´ catholique de Louvain, 54.10, Av. Hippocrate 54, 1200 Brussels, Belgium
Received 1 April 2008; revised 21 April 2008; accepted 28 April 2008
Available online 12 May 2008
Edited by Jesus AvilaAbstract A tetracycline-dependent inducible system was used
to achieve controlled expression of the glutamate transporter 1
(GLT-1) in C6 glioma cells. Non-induced cells show modest glu-
tamate uptake and, in the presence of L-cystine, these cells tend
to release substantial amounts of glutamate. Overnight exposure
to doxycycline increased D-[3H]-aspartate uptake, reaching sim-
ilar capacity as observed in cultured astrocytes. Eﬃcient clear-
ance of exogenously applied glutamate was evidenced in these
cells, even in the presence of L-cystine. The addition of glutamate
(100 lM) to the medium of non-induced cells signiﬁcantly in-
creased their proliferation rate, an eﬀect that was blocked when
the expression of GLT-1 was induced. This suggests that im-
paired glutamate uptake capacity in glioma cells indirectly con-
tributes to their proliferation.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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An eﬃcient glial uptake of excitatory amino acids is essential
in order to maintain low extracellular glutamate concentra-
tions. This ensures an appropriate control of synaptic commu-
nication and prevents chronic glutamate neurotoxicity [1,2].
Thus, impaired functioning of glutamate transporters results
in increased extracellular glutamate, which is a common feature
of several nervous disorders, including motor neuron diseases
[3] and Alzheimers disease [4]. Interestingly, reduced expres-
sion of glial glutamate transporters has been evidenced in hu-
man glioblastoma and in several glioma cell lines [5]. Besides,
an inverse relationship between excitatory amino acid trans-
porter 2 (EAAT-2) expression and tumour grade was demon-Abbreviations: C6-rtTA, transfected C6 cells expressing rtTA; C6-
rtTA-GLT-1, transfected C6 cells with inducible expression of GLT-1;
DHK, dihydrokainic acid; Dox, doxycycline; EAAC1, excitatory
amino acid carrier 1; EAAT-2, excitatory amino acid transporter 2;
GLAST, glutamate and aspartate transporter; GLT-1, glutamate
transporter 1; L-SOS, L-serine-O-sulfate; LTHA, L-()-threo-3-
hydroxyaspartic acid; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide; rtTA, reverse Tet-responsive transcriptional
activator; Xc antiporter, glutamate/cystine exchanger
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doi:10.1016/j.febslet.2008.04.053strated [6] and elevated extracellular glutamate levels have
been measured in animal models of glioma [7]. Together, these
data suggest that compromised glutamate transport could fa-
vour glioma progression by causing excitotoxic damage to nor-
mal brain parenchyma. In addition, glioma cells were shown to
release toxic amounts of glutamate via the abundantly ex-
pressed glutamate-cystine exchanger (Xc antiporter) [5,8,9]. Fi-
nally, there is accumulating evidence that glutamate promotes
the proliferation of invasive glial tumours via autocrine or par-
acrine activation of glutamate receptors [10–13].
Together, these data suggest that the progression of glioma
could be inﬂuenced by their capacity to control the extracellu-
lar concentration of glutamate. Therefore, the present study
aimed at examining the consequence of overexpressing the
high aﬃnity glutamate transporter 1 (GLT-1) (orthologue of
EAAT-2) in a model of rat glioma cells (C6). An inducible sys-
tem was used to achieve controlled expression of this trans-
porter in transfected C6 cells and both substrate uptake by
the cells and glutamate clearance in the extracellular medium
were characterised. Our data indicate that the restoration of
an eﬃcient uptake system may counter the capacity of the cells
to release glutamate and speciﬁcally reduces the glutamate-in-
duced proliferation of C6 cells.2. Materials and methods
2.1. Cell culture
C6 cells (American Type Cell Company ATCC, No. CCL-107) were
cultured in Dulbeccos Modiﬁed Eagles Medium supplemented with
10% foetal bovine serum and 50 lg/ml penicillin–streptomycin. Cul-
tures of astrocytes were prepared from newborn Wistar rat cortices as
previously described [14]. Astrocyte maturation was obtained by main-
taining the cells in culture medium containing 3% serum during 7 days.
All culture reagents were from Invitrogen (Merelbeke, Belgium).
2.2. Transfection and cell selection
To establish the inducible system, cells were transfected with pTet-
On (Westburg, Leusden, The Netherlands) using Lipofectamine (Invit-
rogen). After selection with 600 lg/ml geneticin, a cell clone (C6-rtTA)
expressing the reverse Tet-responsive transcriptional activator (rtTA)
at high level was isolated. These cells were transfected again with a sec-
ond vector carrying a 1719 bp DNA fragment encoding the rat GLT-
1B cloned under the control of the tetracycline inducible promoter
(C6-rtTA-GLT-1). After selection with 600 lg/ml hygromycin and
600 lg/ml geneticin, clones were isolated and examined for their capac-
ity to take up D-[3H]-aspartate after 72 h exposure to 2 lM doxycycline
(Dox).
2.3. Reverse transcription polymerase chain reaction (RT-PCR) and
real-time PCR
RT-PCR and real-time PCR were performed 3 days after plating, as
previously described [15]. Brieﬂy, total RNA was extracted using theblished by Elsevier B.V. All rights reserved.
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cDNA was generated using the iScript cDNA Synthesis kit (Bio-
Rad, Nazareth, Belgium). PCR ampliﬁcations were performed using
Elongase EnzymeMix (Invitrogen) in a total volume of 30 ll contain-
ing 150 ng cDNA template and 1 lM of the appropriate primers (glu-
tamate and aspartate transporter (GLAST) forward: GTGGTAA-
ATTCCTGGAAAGATAAAATATGAC, GLAST reverse: CACAT-
TGTAGAACAGTTTCCAACACCTGGTGC; GLT-1 forward: GA-
GGAGGGGCGTTCCC, GLT-1 reverse: TCCAGGAAGGCATCCAG;
excitatory amino acid carrier (EAAC1) forward: CGAATTCCT-
TCACAAACGCCGGTGCCCATC, EAAC1 reverse: GGCTCTA-
GAACTGCGAGGTCTGAGTGAACG). After 35 cycles of ampliﬁ-
cation (94 C for 30 s, 54–64 C for 45 s, 72 C for 1 min), samples
were electrophoresed on a 1% agarose gel and nucleic acids were visu-
alised by ethidium bromide staining.
Real-time PCR was performed using iCycler IQ multicolor real-
time PCR detection system (Bio-Rad). Forty cycles of ampliﬁcation
(30 s at 95 C, 45 s at 60 C, 15 s at 79 C) were carried out in a total
volume of 25 lL containing 2 ng cDNA template of each sample,
0.375 lM of the appropriate primers (GLT-1 forward: GCCAA-
TACAACCAAGGCAGT, GLT-1 reverse: TTCATCCCGTCCTT-
GAACTC; GAPDH forward: GTCTCCTGTGACTTCAACAG,
GAPDH reverse: AGTTGTCATTGAGAGCAATGC) and the iQ
SYBR Green Supermix (Bio-Rad). For quantitative analysis, ampli-
ﬁcations were performed in the same conditions with serial dilutions of
a mix of the cDNA templates. Each sample was normalised to the
ampliﬁcation of GAPDH and relative quantiﬁcation of mRNA in
the sample were performed using the ‘‘post-run data analysis’’ software
provided with the iCycler system (Bio-Rad).
2.4. Immunocytochemistry
Immunocytochemistry was performed 3 days after plating, as previ-
ously described [16]. Fixed (paraformaldehyde 4% (v/v) for 15 min)
and permeabilised cells (1% Triton X100 (v/v) during 15 min) were
incubated during 1 h with primary antibodies, i.e. a guinea pig anti-
GLAST antibody (1:1000, Chemicon International, Hampshire, Uni-
ted Kingdom), a guinea pig anti-GLT-1 antibody (1:1000, Chemicon
International) and a rabbit anti-EAAC1 antibody (1:100, Gentaur
Molecular Products, Belgium). Secondary antibodies, applied for 1 h
at room temperature were FITC-conjugated anti-rabbit IgG antibody
(1:500) and Cy3-conjugated antiguinea pig IgG antibody (1:1000),
both from Jackson Immunoresearch Laboratory (DePinte, Belgium).
Nuclei were stained during 30 min with the nuclear dye DAPI
(1:5000, Sigma–Aldrich, Bornem, Belgium). Preparations were exam-
ined on Olympus IX70 inverted ﬂuorescent microscope coupled to a
CCD camera and a monochromator (TILL Photonics, Martinsried,
Germany). Digital images were acquired and analysed using the TILL-
visION software.
2.5. Measurement of D-[3H]-aspartate transport activity
Three days after plating (when cells reached conﬂuence), glutamate
transporter activity was measured as previously described [17], using
aspartate as substrate. D-[3H]-aspartate (Perkin–Elmer NEN, Belgium)
was routinely used at a tracer concentration of 50 nM. For saturation
assays, unlabelled L-aspartate was added to achieve ﬁnal concentra-
tions of 1–200 lM. The speciﬁc uptake velocity measured after 6 min
was estimated after subtracting the values obtained in the absence of
Na+. When indicated, the inhibitors L-()-threo-3-hydroxyaspartic
acid (LTHA, 100 lM, Tocris, Bristol, United Kingdom) or dihydro-
kainic acid (DHK, 100 lM, Tocris) were added 6 min before addition
of the substrate.
2.6. Measurement of the extracellular glutamate concentration
The extracellular glutamate concentration was measured by the col-
orimetric method described by Abe and Matsuki [18] with minor mod-
iﬁcations. Three days after plating (when cells reached conﬂuence), 96-
well plates were placed on the surface of a 37 C water bath and incu-
bated during 5 min with 50 lL preheated Krebs buﬀer (25 mMHEPES
pH 7.4, 4.8 mM KCl, 1.2 mM KH2PO4, 1.3 mM CaCl2, 1.2 mM
MgSO4, 6 mM glucose and 140 mM NaCl) before addition of L-gluta-
mate (100 lM) and/or L-cystine (40 lM) (both from Sigma–Aldrich).
At the time indicated 50 lL of culture supernatant were transferred
to a second 96-well plate and mixed with 50 lL of assay mixture con-
sisting of 20 U/mL glutamate dehydrogenase (Roche Diagnostic),2.5 mg/mL b-nicotinamide adenine dinucleotide, 0.25 mg/mL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sig-
ma–Aldrich), 100 lM 1-methoxyphenazine methosulfate (Serva Elec-
trophoresis, Heidelberg, Germany) and 0.1% (v/v) Triton X-100 in
0.2 M Tris–HCl buﬀer (pH 8.2). After 10 min incubation at 37 C,
the reaction was stopped by adding 100 lL of solution of isopropa-
nol/HCl 0.04 N. The amount of MTT formazan was determined by
measuring the absorbance with a microplate reader at 570 nm (test
wavelength) and at 655 nm (reference wavelength). The concentration
of glutamate was estimated from a standard curve which was system-
atically generated using deﬁned concentrations of L-glutamate.
2.7. Cell proliferation assays
C6 cells previously grown for 24 h in low-serum condition (1%) were
seeded in 96-well plates at a density of 3.104 per well. When indicated,
these cultures were supplemented with combinations of L-glutamate
(100 lM), DHK (100 lM) and L-cystine (40 lM) and medium was re-
newed every 24 h. After 72 h (before cells reached conﬂuence), medium
was replaced by 100 lL serum-free medium containing 0.5 mg/mL
MTT. After 60 min incubation at 37 C, the supernatant was aspirated
and the reaction was stopped by adding 100 lL of isopropanol/HCl
0.04 N. The amount of MTT formazan was determined by measuring
the absorbance with a microplate reader (see Section 2.6).3. Results
3.1. Compromised glutamate uptake system in C6 glioma cells
Contrasting with data obtained with cultures of cortical
astrocytes, RT-PCR (Fig. 1A) and immunocytochemical
(Fig. 1C) analyses of C6 cells revealed the absence of GLAST
and GLT-1, the two principal glial glutamate transporters. In
contrast, EAAC1 which is commonly expressed by neurons,
was detected in these glioma cells and measures of D-[3H]-
aspartate (50 nM) uptake in cell monolayers (Fig. 1B) evi-
denced a modest but signiﬁcant glutamate transporter activity
(6.07 ± 0.15 pmol min1 mg prot1, compared to 23.14 ±
0.45 pmol min1 mg prot1 measured in cultured astrocytes).
Additional experiments using glutamate transporters inhibi-
tors indicated that the speciﬁc uptake of D-[3H]-aspartate
was impaired in the presence of L-serine-O-sulfate (not shown)
or LTHA while DHK was without signiﬁcant inﬂuence (Fig.
2C). Together, these data are consistent with previous stud-
ies demonstrating the expression of functional EAAC1 in C6
cells.
3.2. Expression of GLT-1 reinforces the uptake activity in
transfected C6 cells
A tetracycline-driven inducible system was used in order to
generate stably transfected C6 cells in which the transcription
of the recombinant rat GLT-1 could be modulated by exposing
the cells to Dox (C6-rtTA-GLT-1 cells). Real-time PCR exper-
iments showed that exposure of these cells to 2 lM Dox for
72 h increased (by approximately 700%) the level of GLT-1
mRNA (Fig. 2A). Besides, D-[3H]-aspartate (50 nM) uptake
studies showed that Dox elicited a robust reinforcement of their
substrate transport velocity (204% increase as compared to con-
trol, P < 0.001, one-way ANOVA followed by Newman–Keuls
test) reaching values (21.83 ± 0.49 pmol min1 mg prot1), sim-
ilar to those found in cultured astrocytes. Non-linear analysis of
the speciﬁc uptake of isotopic dilutions of D-[3H]-aspartate/L-
aspartate revealed that Dox increased the maximum uptake
capacity by 323% (Vmax values of 17.08 ± 0.61 and 4.04 ± 0.12
nmol min1 mg prot1 for treated and non-treated cells, respec-
tively; P < 0.05, paired Students t-test) and a modiﬁcation of
Fig. 1. Characterisation of high aﬃnity glutamate transporters in C6 glioma cells. The constitutive expression of the glutamate transporter subtypes
was examined in C6 cells and cultured astrocytes (Ast) by RT-PCR (A) and immunocytochemistry (C). GLAST and GLT-1 immunoreactivities were
detected with a Cy3-coupled secondary antibody (red) and EAAC1 immunoreactivity was detected with a FITC-coupled secondary antibody (green).
Cell nuclei were staining with DAPI (blue). Scale bar = 50 lm. Sodium-dependent D-[3H]-aspartate uptake (50 nM) in C6 cells was compared with
values obtained with cultured astrocytes (B). Data shown are means with S.E.M. from three independent experiments performed in triplicate.
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6.86 ± 1.12 lM for treated and non-treated cells, respectively)
(Fig. 2B). The increased substrate uptake velocity observed in
Dox-treated cells was totally inhibited by DHK, conﬁrming
the involvement ofGLT-1.Worth noting, a small but signiﬁcant
DHK-sensitive substrate uptake was detected in cells not ex-
posed to Dox, suggesting that the expression system was not to-
tally silent in the absence of the inducer. Consistently, Vmax
value observed in the non-induced cells appears higher than
the uptake values commonly reported for C6 cells [19]. Finally,
neither GLT-1 expression, nor D-[3H]-aspartate uptake were in-
duced in cells expressing the transactivator only (C6-rtTA cells)
even in the presence of Dox (not shown).
3.3. Expression of GLT-1 increases extracellular glutamate
clearance by C6 cells
The consequence of inducing the expression of GLT-1 in C6
cells was examined by monitoring the kinetic of clearance of
exogenously added glutamate. Preliminary studies revealed that
cultured astrocytes decreased the extracellular glutamate con-
centration from 100 lM to 2.8 ± 0.9 lM within 90 min (Fig.
3A). On the other hand, C6-rtTA cells, C6-rtTA-GLT-1 non-ex-
posed to Dox and non-transfected cells showedmodest capacity
to clear extracellular glutamate (decreased to 64.0 ± 4.1,62.4 ± 4.5 and 71.0 ± 5.7 lM within 180 min, respectively). In
contrast, when exposed to 2 lM Dox for 72 h, C6-rtTA-GLT-
1 eﬃciently decreased the extracellular glutamate concentration
to 15.0 ± 3.9 lM within 180 min. Estimation of the absolute
clearance of glutamate measured during the initial 60 min al-
lowed to calculate that Dox induced a 2.7-fold increase in the
clearance capacity in C6-rtTA-GLT-1 cells (increase from
1.49 ± 0.26 to 5.49 ± 0.46 nmol min1 mg prot1; P < 0.001,
one-way ANOVA followed byNewman–Keuls test). This clear-
ance velocity was close to that measured for cultured astrocytes
(7.46 ± 0.16 nmol min1 mg prot1).
Considering the documented expression of the Xc cystine/
glutamate antiporter in glioma cells, additional glutamate
clearance assays were conducted in the presence of extracellu-
lar cystine (Fig. 3B). In C6-rtTA-GLT-1 non-treated with
Dox, the addition of 40 lM L-cystine elicited a signiﬁcant
accumulation of extracellular glutamate, reaching up to
120 lM at 90 min. In contrast, this cystine-dependent release
of glutamate was not observed in cells where GLT-1 expres-
sion was induced and the capacity of these cells to clear extra-
cellular glutamate was not modiﬁed. Likewise, the addition of
L-cystine to astrocyte cultures was without inﬂuence on the
glutamate clearance velocity, consistent with the strong uptake
activity in these glial cells.
Fig. 2. Inducible expression of functional GLT-1 in transfected C6 glioma cells. (A) Real-time PCR quantiﬁcation of GLT-1 mRNA in C6-rtTA and
C6-rtTA-GLT-1 (with or without treatment with 2 lM Dox). (B) Saturation curves for Na+-dependent D-[3H]-aspartate uptake measured in C6-
rtTA-GLT-1 treated or not with 2 lM Dox. (C) Inﬂuence of glutamate transporters inhibitors DHK and LTHA (both at 100 lM) on D-[3H]-
aspartate uptake (50 nM) in non transfected C6 cells and C6-rtTA-GLT-1 treated or not with 2 lM Dox. Data shown are means with S.E.M. from
three independent experiments performed in triplicate. *P < 0.05, ***P < 0.001, ###P < 0.001 (one-way ANOVA followed by Newman–Keuls test).
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proliferation of C6 glioma cells
When added to the culture medium of C6 cells (not shown),
C6-rtTA (not shown) cells and C6-rtTA-GLT-1 cells (without
Dox) for 72 h, L-glutamate (100 lM) was found to signiﬁcantly
increase cell viability as clearly indicated by the MTT colori-
metric assay (Fig. 4A), which is commonly considered for
the measure of cell proliferation [20]. This eﬀect was strongly
inhibited in cells where GLT-1 expression was induced with
Dox. Conﬁrming the role of GLT-1-mediated clearance of
extracellular glutamate in this inhibition, the ability of gluta-
mate to enhance C6 cell proliferation was restored after
blockade of this transporter with 100 lM DHK. Besides, pro-
liferation of C6-rtTA-GLT-1 cells (without Dox) was sensibly
enhanced when L-cystine (40 lM) was added to the culture
medium (Fig. 4B), an eﬀect that was not blocked by DHK.
The eﬀect of cystine which was reinforced by addition of glu-
tamate (100 lM) was almost totally absent in cells treated with
Dox, suggesting that cystine indirectly promoted C6 cells pro-
liferation by inducing a substantial release of glutamate. In-
deed, in cells treated with Dox, the eﬀect of cystine was also
restored after addition of DHK.4. Discussion
In agreement with earlier reports [21], we herein established
that EAAC1, typically expressed by neurons [22], is the single
high aﬃnity glutamate transporter subtype present in cultured
C6 cells. Accordingly, these cells show modest aspartate up-
take capacity, as compared to cultured astrocytes and the
pharmacological characterisation was consistent with the pres-
ence of EAAC1. Besides, accumulating evidence suggests that
glioma cells may release neurotoxic amount of glutamate via
the Xc antiporter [9]. This antiporter was previously evidenced
in C6 cells [23] where the release of glutamate was shown to
strictly depend on extracellular cystine levels [5]. Accordingly,
our experiments revealed that the addition of L-cystine to the
glutamate-enriched buﬀer of C6 cells causes a signiﬁcant in-
crease in extracellular glutamate, suggesting an eﬃcient release
through the antiporter. Using a tetracycline-dependent induc-
ible system, we then demonstrated that C6 cells engineered to
express the recombinant GLT-1 show a substantially enhanced
aspartate uptake capacity. Expression of GLT-1 also endowed
the cells with the capacity to capture exogenously added gluta-
mate from the extracellular buﬀer, indicating that C6 cells pos-
Fig. 3. Inﬂuence of GLT-1 expression on kinetics of extracellular
glutamate clearance in C6 cells. (A) The extracellular concentration of
glutamate was monitored in cultures of wild-type and transfected C6
cells (exposed or not to Dox) and in cultures of astrocytes. (B)
Inﬂuence of L-cystine (40 lM, closed symbols; control, open symbols)
on extracellular glutamate concentration in cultures of transfected C6
cells (exposed or not to Dox) and in cultures of astrocytes. Data shown
are means with S.E.M. from three independent experiments performed
in quintuplicate. *P < 0.05, **P < 0.01, ***P < 0.001, indicates signiﬁ-
cant diﬀerence between cells exposed or not to L-cystine (one-way
ANOVA followed by Newman–Keuls test).
Fig. 4. Inﬂuence of GLT-1 expression on the proliferation of C6 cells.
C6-rtTA-GLT1 were pre-treated with Dox and exposed to L-glutamate
(100 lM) and/or DHK (100 lM) in a serum-deprived medium during
72 h. Thereafter, cell proliferation was estimated using an MTT
colorimetric assay. Experiments were conducted in the absence (A) or
presence (B) of 40 lM L-cystine. Data shown are means with S.E.M. of
two independent experiments performed in quintuplicate. #P < 0.05,
*P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA followed by
Newman–Keuls test).
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this glial transporter. Even more convincing, the eﬃcient clear-
ance of glutamate was found to be preserved in the presence of
L-cystine indicating that GLT-1-mediated uptake capacity was
suﬃcient to counter balance the glutamate release.
The possibility to manipulate the expression of recombinant
GLT-1 was then proven useful to examine the role of extracel-
lular glutamate in the control of glioma cell proliferation. Re-
cent studies indicate that beside its well-documented
excitotoxic property toward neuronal cells, glutamate may
have a trophic eﬀect on glioma cells. Thus, the release of glu-
tamate through the Xc antiporter would indirectly contribute
to the control of cell proliferation via activation of glutamate
receptors [11,12]. Accordingly, the exposure of cultured C6
cells to exogenously added glutamate increases their prolifera-
tion rate, an eﬀect that was totally abolished when the expres-
sion of GLT-1 was induced. Though cell transfection is
frequently associated with altered cell proliferation, the risk
of experimental bias was limited, thanks to the inducible sys-tem which permits the use of a single clonal cell line for the en-
tire study. Experiments were conducted in a low-serum
medium in order to achieve a better control of extracellular
glutamate and to speciﬁcally address the inﬂuence mediated
by this amino acid. In the absence of GLT-1 expression (not
induced), the proliferative eﬀect of glutamate was mimicked
by addition of L-cystine. This enhanced proliferation appeared
strictly dependent on the release of glutamate as it was also re-
duced in cell expressing GLT-1. As enhancing the glutamate
uptake activity resulted in a decreased proliferation rate, one
may assume that glutamate was not promoting the metabolic
activity of the C6 cells. Indeed, the trophic eﬀect of glutamate
in glioma cells was previously assigned to the activation of
ionotropic or metabotropic glutamate receptors and their
pharmacological blockade was shown to limit glioma growth
in vitro and in vivo [10–13]. Noteworthy, mGlu2/3 metabotro-
pic receptors, known to support proliferation of glioma cells
[10,11], have been characterised in C6 cells [24].
In summary, these results demonstrate that the restoration
of an eﬃcient glial glutamate uptake activity in a model of gli-
oma cells may counter their capacity to release glutamate and
speciﬁcally reduces the glutamate-induced cell proliferation. A
1852 N. Vanhoutte, E. Hermans / FEBS Letters 582 (2008) 1847–1852working hypothesis would consider that in astrocytes, the
putative Xc antiporter ensures an eﬃcient uptake of cystine,
but should not exert a signiﬁcant inﬂuence on the extracellular
concentration of glutamate. Likely, glutamate released
through this antiporter is rapidly removed through reuptake
by high aﬃnity glial transporters, precluding any sustained
interaction with ionotropic or metabotropic receptors. Though
previous studies have shown that manipulating the endoge-
nous expression of GLT-1 in C6 cells could lead to the produc-
tion of an aberrant transporter transcript [25], these data
suggest that further in vivo studies should consider the option
of enhancing glutamate uptake by glioma cells to reduce their
invasive behaviour.
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